Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Advanced Solid Malignancies 1Advanced Liver Cancers 1

Interventions

pembrolizumab 39Bevacizumab 25Cyclophosphamide 23Blood Specimen Collection 19Standard of Care 17Nivolumab 17Carboplatin 17Paclitaxel 15Exercise 15Gemcitabine 14atezolizumab 13Pemetrexed 13Cisplatin 13Radiotherapy 11Fluorouracil 11Doxorubicin 11Cetuximab 10130-nm albumin-bound paclitaxel 10durvalumab 9Rituximab 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9Biopsy 9abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Prednisone 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Tiragolumab × 90 days × Clear all
NCT05862285 2026-05-12

UmbrellaMAX

Hoffmann-La Roche

Phase 3 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

NCT05394337 2026-05-05

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡